SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer

Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) has expanded its collaboration with AstraZeneca to enhance breast and prostate cancer detection through advanced AI technology. The partnership focuses on developing an optimized next-generation sequencing (NGS) solution that employs AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway.

The companies have already developed a prototype demonstrating improved sensitivity in mutation detection. SOPHiA GENETICS will implement a Privileged Access Program for selected clinical laboratories, with broader commercial availability expected in 2026. The program includes a multi-center real-world evidence study to validate the technology's effectiveness in clinical settings.

Positive

• Development of enhanced NGS solution with improved mutation detection sensitivity
• Expansion of global testing network for PIK3CA/AKT1/PTEN pathway in tissue and liquid biopsy
• Partnership with major pharmaceutical company AstraZeneca strengthens market position
• Planned commercial launch in 2026 with validated real-world evidence

Negative

• Extended timeline to commercial availability (2026)
• Initial access limited to selected laboratories through Privileged Access Program

News Market Reaction – SOPH

+18.37% 4.4x vol

22 alerts

+18.37% News Effect

+6.2% Peak Tracked

-15.4% Trough Tracked

+$41M Valuation Impact

$265.58M Market Cap

4.4x Rel. Volume

On the day this news was published, SOPH gained 18.37%, reflecting a significant positive market reaction. Argus tracked a peak move of +6.2% during that session. Argus tracked a trough of -15.4% from its starting point during tracking. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $41M to the company's valuation, bringing the market cap to $265.58M at that time. Trading volume was very high at 4.4x the daily average, suggesting strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate cancer by developing an optimized next generation sequencing (NGS) solution that leverages SOPHiA GENETICS's AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway.

The PIK3CA/AKT1/PTEN pathway is a key molecular signaling network that regulates how cells grow and survive, and its disruption is linked to the development of many cancers, including breast and prostate cancer. The PTEN gene, when altered, can contribute to cancer development and resistance to treatment. As part of this collaboration, the companies have developed an optimized NGS solution that deploys AI agents to analyze and detect genomic mutations across the full PTEN gene. A prototype of the enhanced solution has already demonstrated improved sensitivity in its ability to detect complex mutations across the pathway.

As part of the agreement, SOPHiA GENETICS will roll out a Privileged Access Program to selected clinical laboratories specializing in breast and prostate cancer research to validate sensitivity in a real-world setting, with broader commercial availability expected in 2026, alongside a multi-center real-world evidence study to further test its effectiveness. SOPHiA GENETICS's global network will also help drive adoption of advanced PIK3CA/AKT1/PTEN testing in both tissue and liquid biopsy to expand patient access to precision therapies.

"Each day brings new insights that transform our understanding of cancer. Partnering with innovative biopharma leaders like AstraZeneca allows us to translate these discoveries into action for breast and prostate cancer patients worldwide, representing another step forward in our mission to democratize data-driven medicine." said Ross Muken, President, SOPHiA GENETICS.

The expanded partnership highlights the shared commitment of SOPHiA GENETICS and AstraZeneca to drive innovation in precision oncology and to ensure that patients across the globe can benefit from advanced genomic testing and targeted treatments. To learn more, connect with SOPHiA GENETICS at the World CB & CDx Summit in Boston, MA from September 22-25, 2025.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn. 

About SOPHiA GENETICS  

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. 

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements:  
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-expands-collaboration-with-astrazeneca-to-enhance-detection-of-breast-and-prostate-cancer-302562478.html

SOURCE SOPHiA GENETICS

FAQ

What is the new collaboration between SOPHiA GENETICS (SOPH) and AstraZeneca?

SOPHiA GENETICS and AstraZeneca are collaborating to develop an AI-powered NGS solution for detecting genetic mutations in the PIK3CA/AKT1/PTEN pathway to improve breast and prostate cancer diagnosis and treatment.

When will SOPHiA GENETICS' new cancer detection technology be commercially available?

The enhanced NGS solution is expected to be commercially available in 2026, following validation through a Privileged Access Program and multi-center real-world evidence study.

How does SOPHiA GENETICS' new cancer detection technology work?

The technology uses AI algorithms and next-generation sequencing (NGS) to analyze and detect genomic mutations across the full PTEN gene and PIK3CA/AKT1/PTEN pathway, which are crucial in cancer development.

What are the key benefits of SOPHiA GENETICS' expanded collaboration with AstraZeneca?

The collaboration aims to improve cancer diagnosis accuracy, expand patient access to precision therapies, and validate the technology through real-world testing in clinical laboratories specializing in breast and prostate cancer research.

How will SOPHiA GENETICS validate their new cancer detection technology?

The company will implement a Privileged Access Program with selected clinical laboratories and conduct a multi-center real-world evidence study to validate the technology's effectiveness in clinical settings.